Massive Bio, Optellum Partner to Advance Lung Cancer Trial Access

Massive Bio and Optellum have announced a strategic collaboration designed to connect early lung cancer detection with faster access to clinical trials, potentially addressing one of the most persistent challenges in oncology research and patient care.

The partnership combines Optellum’s artificial intelligence-powered lung cancer detection technology with Massive Bio’s AI-driven clinical trial matching platform. The companies say the integration is the first of its kind and aims to ensure that patients identified as being at high risk for lung cancer are rapidly evaluated for clinical trial opportunities before treatment windows narrow.

Lung cancer remains the leading cause of cancer-related deaths globally, despite significant advances in diagnosis and treatment. Experts note that early detection dramatically improves patient outcomes. Five-year survival rates can increase from approximately 9% in patients diagnosed at advanced stages to around 64% when the disease is identified early. However, many patients who are identified as high risk through imaging never gain access to clinical trials that could provide innovative treatment options.

The newly announced collaboration seeks to close this gap by creating a streamlined pathway from detection to clinical trial consideration.

At the center of the initiative is Optellum’s Lung Cancer Prediction (LCP) AI platform, which has gained recognition as the first FDA-cleared clinical decision support software for early-stage lung cancer. The technology analyzes radiology reports and computed tomography (CT) scans to identify lung nodules that may indicate a high risk of cancer. By helping clinicians recognize suspicious findings earlier, the system aims to accelerate diagnostic and treatment decisions.

Under the agreement, de-identified patient signals generated by Optellum’s platform will be processed through Massive Bio’s AI-based clinical trial matching system. The platform evaluates patient characteristics and compares them with eligibility criteria for active non-small cell lung cancer (NSCLC) clinical trials. It then generates physician-focused reports highlighting geographically accessible studies that may be relevant to individual patients.

The companies emphasize that the workflow is designed to protect patient privacy while keeping physicians in control of treatment and referral decisions. The process does not require patients or healthcare providers to independently search through complex clinical trial databases, a barrier that has historically limited participation in cancer research.

According to Massive Bio, patients identified through Optellum’s AI represent some of the most time-sensitive candidates for clinical research because they are often detected before a formal diagnosis is confirmed and while potentially curative treatment options remain available.

Company executives believe the collaboration could have broader implications beyond individual patient care. Clinical trial enrollment remains a major challenge for the pharmaceutical and biotechnology industries, with many studies struggling to recruit sufficient participants. Delays in patient identification can slow research timelines and hinder the development of new therapies.

By identifying high-risk individuals earlier and matching them with suitable studies in real time, the companies hope to accelerate both clinical research and access to emerging treatments.

Arturo Loaiza-Bonilla, Chief Medical AI Officer at Massive Bio, said the partnership creates an opportunity to connect high-risk imaging findings with relevant clinical trials at the right moment in a patient’s care journey. Meanwhile, Massive Bio Chief Financial Officer Toygun Rauf Onaran noted that the initiative could help address long-standing inefficiencies in clinical trial recruitment.

Optellum Chief Executive Officer Johnathan Watkins added that early detection only fulfills its promise when it leads patients to the best available care options, including access to cutting-edge clinical research.

As artificial intelligence becomes increasingly integrated into healthcare, the collaboration highlights a growing trend toward using advanced analytics not only to identify disease earlier but also to connect patients more efficiently with potentially life-changing treatment opportunities. For lung cancer patients, where timing can significantly influence outcomes, the partnership could represent an important step toward more proactive and personalized care.